Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
Want to see GLUE full AI Analyst Report?
Top Page
Monte Rosa Therapeutics
(NASDAQ:GLUE)
Select Model
Select Model
Rating:54Neutral
Price Target:
$19.00
▼(-3.94% Downside)
Action:ReiteratedDate:04/22/26
The score is mainly held back by weak financial performance (ongoing losses and 2025 cash burn) despite a relatively strong balance sheet. Technicals are supportive with an established uptrend, but overbought momentum signals increase near-term risk. Valuation is neutral-to-weak given the negative P/E and no dividend support.
Positive Factors
Proprietary QuEEN platform
Monte Rosa's QuEEN platform is a durable competitive asset: it enables targeting 'undruggable' proteins and can generate multiple discovery programs across indications. A platform-driven model supports repeated value creation via internal pipelines and partner deals over the next several years.
Negative Factors
Return to cash burn and cash flow volatility
The swing from positive to negative cash flow within one year signals volatile funding needs and execution timing risk. Persistent or recurring cash burn increases probability of future financing, partner dependence, or program prioritization that can constrain long-term development plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary QuEEN platform
Monte Rosa's QuEEN platform is a durable competitive asset: it enables targeting 'undruggable' proteins and can generate multiple discovery programs across indications. A platform-driven model supports repeated value creation via internal pipelines and partner deals over the next several years.
Read all positive factors
Monte Rosa Therapeutics (GLUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.50B
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue Growth63.54%
EPS Growth40.61%
CountryUS
Employees142
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding80,015,670
10 Day Avg. Volume836,939
30 Day Avg. Volume1,148,653
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)5.59
Price to Sales (P/S)10.53
P/FCF Ratio-47.37
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue9.17
Enterprise Value/Gross Profit9.49
Enterprise Value/Ebitda-26.28
Forecast
1Y Price Target
$31.50Price Target Upside59.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$56.75M
Monte Rosa Therapeutics Business Overview & Revenue Model
Company Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an o...
How the Company Makes Money
Monte Rosa Therapeutics generates revenue primarily through collaboration and licensing arrangements with larger pharmaceutical partners rather than from product sales, as it is a clinical-stage company. Under these partnerships, the company may e...
Monte Rosa Therapeutics Earnings Call Summary
Earnings Call Date:Mar 20, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Positive Updates
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Negative Updates
Lower than Expected Biomarker Positivity
In the MRT-2359 Phase 1/2 study, there was a considerably lower than expected frequency of tumors with high L or N-MYC expression, affecting lung cancer and neuroendocrine tumor cohorts.
Read all updates
Q4-2024 Updates
Positive
Negative
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Read all positive updates
Company Guidance
During the Monte Rosa Therapeutics conference call held on March 20, 2025, several key metrics were discussed regarding the company's clinical and preclinical programs. The Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader, demonstrated significant pharmacodynamic effects with over 90% VAV1 degradation and up to 99% cytokine secretion inhibition, supporting progression to Phase 2 trials. The NEK7 program is on track for an IND submission in the first half of the year, with preclinical data showing potent NEK7 degradation and favorable safety profiles. In oncology, promising early data from the MRT-2359 program in castration-resistant prostate cancer showed a confirmed partial response and two stable diseases among three patients, prompting a focus on this indication. Monte Rosa plans to advance these programs with a strong cash runway extending into 2028.Monte Rosa Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
45
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 123.67M | 75.62M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 115.32M | 67.50M | -6.22M | -8.56M | 0.00 |
| EBITDA | -45.85M | -72.99M | -137.09M | -108.64M | -70.75M |
| Net Income | -38.63M | -72.70M | -135.35M | -108.50M | -73.96M |
Balance Sheet | |||||
| Total Assets | 448.66M | 438.73M | 303.75M | 342.39M | 366.33M |
| Cash, Cash Equivalents and Short-Term Investments | 377.10M | 372.15M | 232.41M | 262.83M | 346.07M |
| Total Debt | 39.19M | 42.72M | 46.04M | 47.00M | 0.00 |
| Total Liabilities | 215.60M | 215.80M | 124.50M | 70.98M | 18.81M |
| Stockholders Equity | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M |
Cash Flow | |||||
| Free Cash Flow | -27.50M | 38.01M | -62.84M | -105.38M | -69.09M |
| Operating Cash Flow | -22.80M | 42.00M | -43.80M | -92.47M | -59.36M |
| Investing Cash Flow | -101.83M | -44.45M | 88.80M | -219.22M | -9.65M |
| Financing Cash Flow | 30.35M | 98.89M | 27.49M | 20.47M | 377.56M |
Monte Rosa Therapeutics Technical Analysis
Positive
19.78
Price Trends
17.54
Positive
18.24
Positive
12.88
Positive
Market Momentum
0.41
Negative
69.69
Neutral
94.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLUE, the sentiment is Positive. The current price of 19.78 is above the 20-day moving average (MA) of 16.84, above the 50-day MA of 17.54, and above the 200-day MA of 12.88, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 69.69 is Neutral, neither overbought nor oversold. The STOCH value of 94.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLUE.
Monte Rosa Therapeutics Risk Analysis
Monte Rosa Therapeutics disclosed 85 risk factors in its most recent earnings report. Monte Rosa Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monte Rosa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $490.42M | -7.74 | -27.80% | ― | -100.00% | -2365.81% | |
54 Neutral | $1.50B | -33.72 | -15.12% | ― | 63.54% | 40.61% | |
53 Neutral | $1.88B | -8.74 | -269.56% | ― | 550.00% | -107.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $356.36M | -35.28 | -0.04% | ― | ― | 44.89% | |
46 Neutral | $903.62M | -33.83 | -19.77% | ― | -44.82% | -97.67% |
* Healthcare Sector Average
GLUE
Monte Rosa Therapeutics
18.80
14.17
306.05%
CTMX
CytomX Therapeutics
4.18
3.22
334.96%
FULC
Fulcrum Therapeutics
7.36
1.63
28.45%
MNPR
Monopar Therapeutics Inc
53.25
9.89
22.81%
INBX
Inhibrx Biosciences Inc
128.79
116.46
944.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.